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Bone marrow transplantation (BMT) can give rise to 
donor-derived osteopoiesis in mice and humans; how-
ever, the source of this activity, whether a primitive 
osteoprogenitor or a transplantable marrow cell with 
dual hematopoietic and osteogenic potential, has eluded 
detection. To address this issue, we fractionated whole 
BM from mice according to cell surface immunophe-
notype and assayed the hematopoietic and osteopoi-
etic potentials of the transplanted cells. Here, we show 
that a donor marrow cell capable of robust osteopoi-
esis  possesses a surface phenotype of c-Kit+ Lin− Sca-1+ 
CD34−/lo, identical to that of the long-term repopulat-
ing hematopoietic stem cell (LTR-HSC). Secondary BMT 
studies demonstrated that a single marrow cell able to 
contribute to hematopoietic reconstitution in primary 
recipients also drives robust osteopoiesis and LT hema-
topoiesis in secondary recipients. These findings indicate 
that LTR-HSC can give rise to progeny that differentiate 
to osteoblasts after BMT, suggesting a mechanism for 
prompt restoration of the osteoblastic HSC niche follow-
ing BM injury, such as that induced by clinical BMT pre-
parative regimens. An understanding of the mechanisms 
that regulate this differentiation potential may lead to 
novel treatments for disorders of bone as well as meth-
ods for preserving the integrity of endosteal hematopoi-
etic niches.
Received 23 January 2012; accepted 30 January 2013; advance online  
publication 16 April 2013. doi:10.1038/mt.2013.36
INTRODUCTION
Bone and bone marrow (BM) are anatomically contiguous and 
harbor cell types that are functionally interrelated.1 Conceivably, 
then, a stem cell could give rise to both hematopoietic and osteo-
poietic progeny under the control of a specific genetic program 
or particular environmental cues. Several investigators have 
independently demonstrated that BM transplantation (BMT) 
results in donor-derived osteopoiesis early after this procedure 
in mice,2–6 whereas others have identified donor osteoblasts after 
transplantation in humans.7–9 Molecular analysis of transplanted, 
gene-marked marrow cells in mice revealed a common retroviral 
integration site in hematopoietic and osteopoietic cells suggesting 
a dual differentiation capacity of primitive marrow progenitors.2 
The functional capacity of the differentiated osteopoietic cells has 
been demonstrated by their ability to secure clinical improve-
ment in children with osteogenesis imperfecta7,8,10 and, more 
recently, by amelioration of the osteogenesis imperfecta pheno-
type in a mouse model.5 These reports establish a link between 
transplanted marrow cells and osteopoiesis, but lack the neces-
sary evidence to identify the source of this osteopoietic activity. 
Identifying a transplantable osteoprogenitor or perhaps a putative 
dual hematopoietic-osteopoietic progenitor could be key to our 
understanding of the biology of marrow transplantation and the 
hematopoietic stem cell (HSC) niche. Such insights could lead in 
turn to the development of novel cell therapies based on endog-
enous biologic differentiation potential.
Using secondary BMT assays, we show here that a single mar-
row cell able to contribute to hematopoietic reconstitution in 
primary recipients drives both osteopoiesis and long-term (LT) 
hematopoiesis in secondary recipients. These findings, together 
with evidence that this bipotential cell satisfies stringent crite-
ria for stemness, suggest a novel mechanism for hematopoietic-
osteopoietic maintenance that could be harnessed for medical 
interventions.
RESULTS
Transplantable osteoprogenitor activity resides 
within the primitive hematopoietic progenitor 
population
Our previous studies indicated that marrow cells unable to adhere 
to plastic in vitro are more robust transplantable osteoprogenitors 
than are adherent mesenchymal stem/stromal cells (MSCs) after 
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systemic transplantation.2 This finding, together with detection of 
the Sca-1 marker on primary osteoblasts derived from bone explants 
(Figure  1a) and MSCs (Figure 1b), suggested that the putative 
transplantable marrow osteoprogenitor resides within the nonad-
herent Sca-1+ population. To identify this osteoprogenitor popula-
tion in the non(plastic)-adherent BM cells, we transplanted 2 × 105 
Lin− (Gr1, CD11b, CD4, CD8, B220, Ter119) Sca-1+ cells from a 
green fluorescent protein (GFP) expressing transgenic mouse11 into 
lethally irradiated recipient mice (Figure 1c,d). Short-term and LT 
hematopoiesis were reconstituted as was a mean (± SD) osteopoietic 
engraftment of 15.4 ± 4.3% (Figure 1e). In contrast the Lin− Sca1− 
fraction of marrow, reconstituted short-term but not LT hemato-
poiesis and did not give rise to osteoblasts (Figure 1f). To exclude 
contamination of these grafts by a rare, unidentified highly prolif-
erative osteoprogenitor among the adherent MSCs, we transplanted 
1 × 106 MSCs from a transgenic GFP-expressing mouse and found 
a median of only 1.8% donor-derived osteopoiesis (range, 0–2.5%; 
n = 5) consistent with our prior results.2 These data indicate that the 
Lin− Sca-1+ fraction of nonadherent cells contains all, or is at least 
highly enriched for, the transplantable osteoprogenitor activity.
To further define the phenotype of the transplantable osteo-
progenitor, we fluorescence-activated cell sorting (FACS)-sorted 
c-Kit+ Sca-1+ cells from lineage-depleted (Lin−) GFP transgenic 
marrow (Figure 1g) and transplanted 2,000 of these KLS cells 
(c-Kit+ Lin− Sca-1+) into each of five lethally irradiated mice. 
At 3 weeks post-transplantation, we observed >90% hematopoi-
etic engraftment in each mouse and a mean (± SD) osteopoietic 
engraftment of 17.2 ± 5.6% (Figure 1h).
To investigate whether all of the osteopoietic activity of 
transplanted BM resides within the KLS cell fraction, we trans-
planted 1,000 FACS-sorted GFP+ KLS cells or 1,000 GFP+ BM 
cells depleted of KLS cells into lethally irradiated mice (n = 10 per 
group). At 3 weeks post-transplantation, the KLS grafts contrib-
uted to both hematopoiesis and osteopoiesis in all mice identical 
to the outcome shown in Figure 1h, whereas the marrow graft 
devoid of KLS cells gave rise to short-term hematopoiesis, but 
failed to engraft in bone, indistinguishable from the outcome after 
transplantation of Lin− Sca-1− cells (Figure 1f).
Transplantable osteoprogenitor activity exclusively 
resides among multilineage hematopoietic stem/
progenitor cells
We FACS-sorted KLS cells into CD34+ and CD34− fractions 
(Figure 2a) and transplanted 200 of each cell population into 
lethally irradiated mice. In recipients of the CD34− KLS cells 
(n = 7), the mean (± SD) osteopoietic engraftment was 3.29 ± 1.34%, 
compared with 0.91 ± 0.38% in recipients (n = 4) of the CD34+ 
KLS cells (P = 0.007, Figure 2b). The low level of engraftment by 
the CD34+ cells was significantly higher (P = 0.02) than in the 
negative control (0.17 ± 0.06%, n = 3), indicating that the CD34+ 
KLS cells, although much less robust osteoprogenitors than their 
CD34− counterparts, still possessed osteopoietic activity.
To determine the extent of apparent hematopoietic cell dif-
ferentiation while retaining osteoprogenitor potential, we trans-
planted multipotent progenitors (CD244+ CD150− CD48−),12 
common lymphoid progenitors (c-Kit+ Lin− Sca-1+ CD127+)13 
or common myeloid progenitors (c-Kit+ Lin− Sca-1−/lo 
CD127− CD34+FcγRlo)14 into lethally irradiated mice (n = 7 
per group). None of these three cell populations contributed to 
osteopoiesis by 3 weeks post-transplantation (Figure 2c). These 
findings implicate the population of CD34− KLS cells, which are 
highly enriched for LT repopulating HSCs (LTR-HSCs),15 as the 
most robust transplantable osteoprogenitors within BM.
Figure 1 Sca-1+ marrow cells engraft in bone and bone marrow 
(BM). Flow cytometric analysis demonstrating Sca-1 expression in pri-
mary cultures of (a) osteoblasts and (b) mesenchymal stem cells. Sca-1+ 
(—), isotype control (- - -). (c,d) Flow cytometric analysis of marrow 
cells showing the Lin− gate (~4.5%) and of Lin− cells showing the Sca-
1+ gate (~1–2%), respectively. Representative immunohistochemical 
staining of green fluorescent protein (GFP) revealing donor-derived cells 
(orange) (e) in the bone and marrow cavity of mice (n = 5) transplanted 
with Lin− Sca-1+ cells (f) but only in the BM of mice (n = 5) trans-
planted with Sca-1− cells. Osteoblasts and osteocytes are indicated by 
thick and thin arrows, respectively. (g) Flow cytometric dot plot showing 
the gate of c-Kit+ Sca-1+ cells sorted from the Lin− cells analyzed in c. 
(h) Representative immunohistochemical staining of bone and BM from 
mice (n = 7) transplanted with GFP+ KLS cells (orange). Osteocytes and 
osteoblasts are designated as in f. (i) Negative control specimens from a 
mouse transplanted with KLS cells and stained with an isotype primary 
antibody or (j) from a wild-type mouse and stained with anti-GFP anti-
serum. Bar = 50 μm.
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Hematopoietic stem/primitive progenitor cells 
specifically block transplantable osteoprogenitor 
activity
If the CD34− KLS marrow cells, indicative of the pool of primi-
tive hematopoietic stem/progenitor cells, are the potent trans-
plantable marrow osteoprogenitors as our data suggests, then 
donor-derived osteopoiesis after BMT, experimentally iden-
tified by GFP expression, should be competitively inhibited 
by cotransplantation of unlabeled CD34− KLS cells. To test 
this prediction, we transplanted 2 × 105 unfractionated, GFP-
expressing marrow cells into lethally irradiated recipients either 
alone or with 2,000 unlabeled KLS cells, 20,000 KLS cells or 300 
CD34− KLS cells (n = 5 mice per group) as competitor cells. At 
3 weeks post-transplantation, the animals transplanted without 
competitor cells showed >95% GFP+ cells in whole BM as well as 
in the KLS marrow population (Figure 3a,b) and a mean (± SD) 
of 14.14 ± 2.11% donor osteopoiesis (Figure 3c). Both the lower 
and higher doses of unlabeled KLS competitors significantly 
reduced the percent contribution of the unfractionated GFP+ 
cells to short-term hematopoiesis (P = 0.008 and P < 0.001, 
respectively) (Figure 3a) as well as the reconstitution of the KLS 
progenitor pool (P = 0.04 and P < 0.001, respectively) (Figure 
3b). Unlabeled CD34− KLS cells did not reduce the recovery of 
GFP+ hematopoiesis (P = 0.13) (Figure 3a), consistent with the 
abundance of mature precursors in unfractionated marrow and 
the relative paucity of such progenitors among CD34− KLS cells. 
By contrast, osteopoietic engraftment of GFP+ cells was strik-
ingly diminished by cotransplantation with only 300 CD34− KLS 
cells (P < 0.001) (Figure 3c). These stem/primitive progenitor 
cells, identified by the CD34− KLS phenotype, demonstrated a 
100- to 200-fold greater capacity to inhibit osteopoietic engraft-
ment than did unsubfractionated KLS cells.
LTR-HSC have dual hematopoietic-osteopoietic 
differentiation capacity
Our data suggest a dual hematopoietic-osteopoietic differentia-
tion capacity for marrow cells exhibiting the CD34− KLS phe-
notype. Although not strictly homogeneous, CD34− KLS cells 
are considered to represent LTR-HSC.15 Collectively, then, our 
data raise the possibility that the LTR-HSC possess an osteo-
poietic differentiation potential. To rigorously test this idea, we 
transplanted single FACS-sorted GFP+ KLS cells into lethally 
irradiated mice (n = 60) that were also given 1 × 105 Sca-1− 
wild-type marrow cells to support short-term hematopoietic 
recovery. At 16 weeks post-transplantation, four of the mice 
showed a contribution to blood leukocytes (3–52%) and the 
BM (1.3–69%) from the single infused GFP+ cell (Figure 4a). 
Unfractionated BM cells (3 × 106) from the three mice with 
Figure 2 Engraftment of donor KLS cells. (a) Flow cytometric analysis of KLS cells showing the sort gates for the CD34−/lo and CD34bright subsets. 
(b) Comparison of osteopoietic engraftment rates for CD34bright versus CD34−/lo KLS cells. Mean (± SD) percentages of donor osteoblasts and osteo-
cytes are shown. (c) Osteopoietic engraftment of multipotent progenitors (MPP), common myeloid progenitors (CMP), and common lymphoid 
progenitors (CLP). Positive controls (Pos) were mice transplanted with 1 × 106 unfractionated GFP+ marrow cells; negative controls (Neg) were mice 
transplanted with unlabeled marrow. GFP, green fluorescent protein.
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Figure 3 Competitive inhibition by primitive hematopoietic cells. (a) Reconstitution of whole bone marrow, (b) KLS hematopoietic marrow 
compartment, or (c) bone cell compartment, after transplantation of 2 × 105 GFP-expressing marrow cells alone (control) or with 2 × 103 or 2 × 104 
 unlabeled KLS cells, or 300 CD34− KLS competitor cells. Mean (± SD) percentages of GFP-expressing cells were determined by flow cytometry 
(in a,b) or immunohistochemical staining (in c). GFP, green fluorescent protein.
0
Control 2,000
KLS
20,000
KLS
300
KLS
CD34−
Control 2,000
KLS
20,000
KLS
300
KLS
CD34−
Control 2,000
KLS
20,000
KLS
300
KLS
CD34−
0
25
50
75
100
4
8
%
 G
FP
+
 
ce
lls
%
 G
FP
+
 
ce
lls
0
Whole bone marrow KLS marrow cells
Bone cells
P < 0.001
P = 0.007
25
50
75
100
%
 G
FP
+
 
ce
lls 12
16
a b c
1226 www.moleculartherapy.org vol. 21 no. 6 june 2013
© The American Society of Gene & Cell Therapy
HSC Differentiate to Osteoblasts in the Stem Cell Niche
26–69% GFP+ marrow reconstitution were then transplanted 
into lethally irradiated secondary recipients (n = 4 mice per 
primary recipient). At 3 weeks after secondary transplantation, 
all mice showed GFP+ hematopoiesis in blood (leukocytes, 
56–75%, Figure 4b; erythrocytes, 32–42%; platelets, 40–72%), 
with 38–59% GFP+ engraftment in the BM (Figure 4b) of killed 
mice (n = 2 per primary recipient) demonstrating a contribu-
tion to short-term hematopoiesis. Evidence for self-renewal and 
LT hematopoietic repopulating capacity of the single KLS cells 
was provided in the secondary recipients (n = 2 per primary 
recipient transplanted), which were maintained for 18 weeks 
following transplantation. At that time, blood showed 69–89% 
GFP+ leukocytes, 52–99% GFP+ erythrocytes, and 45–97% 
GFP+ platelets; GFP+ donor engraftment was also observed in 
the BM (31–99%) (Figure 4c).
Strikingly, donor-derived (GFP+) osteopoiesis was evident 
within the epiphysis and metaphysis of the long bones of these 
secondary recipients (5.1–8.0%) at 3 weeks after transplanta-
tion, the optimal time to assess osteopoietic engraftment.16 
Double immunohistochemical staining for collagen I and 
GFP (Figure  5a) and for osteocalcin and GFP (Figure 5b) 
identified the GFP+ cells as osteoblasts and osteocytes. 
Immunofluorescence microscopy shows donor-derived osteo-
blasts and osteocytes (Figure 5c). Both microscopy studies dem-
onstrated donor-derived osteopoietic cells in clusters, a pattern 
consistent with our previous observations after conventional 
transplantation of unfractionated BM.16
To further validate GFP expression in osteoblasts, we FACS-
sorted culture-expanded cells obtained from the bone of a second-
ary recipient to enrich for GFP expression, attaining a population 
that was >97% GFP-positive (Figure 5d). Reverse transcrip-
tase-PCR demonstrated that these plastic-adherent GFP+ cells 
expressed osteopontin, collagen I, and osteocalcin, but not CD45, 
indicative of an osteoblast phenotype (Figure 5e). Quantitative 
reverse transcriptase-PCR demonstrated comparable expression 
of five bone-specific genes to the ubiquitously expressed GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) in this cell popu-
lation confirming the osteoblast phenotype of these GFP+cells, 
which must be progeny of the originally transplanted, single GFP-
expressing cell (Figure 5f).
Our data demonstrate individual cells expressing mark-
ers of LTR-HSC origin (GFP) and osteoblasts/osteocytes sug-
gesting differentiation of LTR-HSC to bone cells. Fusion of 
donor-derived hematopoietic cells with host osteoblasts in 
the secondary recipients was excluded by fluorescence in situ 
hybridization in culture-expanded, donor-derived (Y chromo-
some) osteoblasts (Figure 6).
DISCUSSION
In contrast to purported rare instances of HSC plasticity which 
have been effectively refuted,17 our data indicate a reproduc-
ible, robust osteopoietic differentiation of the LTR-HSC. This 
study was founded on several prior observations. First, we2,18 and 
 others3–6 have shown that transplantation of BM cells (>99.9% 
hematopoietic cells) leads to donor-derived osteopoiesis in mice. 
Second, while MSCs are thought to be marrow osteoprogenitors, 
we have shown that non(plastic)-adherent marrow cells are far 
more robust osteoprogenitors than MSCs after intravenous trans-
plantation.2 Third, the level of donor-derived osteopoiesis is satu-
rable18 suggesting the transplantable osteoprogenitor engrafts at 
distinct, saturable sites in the marrow microenvironment. Finally, 
after transplantation, early hematopoietic engraftment seems to 
occur at discrete sites within the marrow space,19–21 and donor-
derived osteopoiesis invariably mirrors the clusters of donor 
hematopoietic engraftment16,19 suggesting a common niche for 
both regenerating activities.
Our pilot experiment showing that transplanted Lin−  Sca-1+ 
cells (2 × 105) resulted in a level of osteopoietic engraftment similar 
to what we observed after transplantation of tenfold more (2 × 106) 
unfractionated BM cells18 supported our hypothesis that primi-
tive hematopoietic cells have dual hematopoietic- osteopoietic 
differentiation capacity. Had the observed engraftment been due 
to a contaminating adherent MSC then transplantation of an 
equal number of purified MSCs should have resulted in a similar 
amount of engraftment rather than the nearly tenfold less that was 
observed.
Figure 4 Dual hematopoietic-osteopoietic engraftment of a single 
KLS cell. (a) Flow cytometric analysis showing high-level green fluo-
rescent protein (GFP) expression among blood leukocytes (WBC) and 
unfractionated marrow cells (BM) from the primary recipient. (b) Flow 
cytometric analysis for GFP positivity among blood leukocytes and 
unfractionated marrow cells from a secondary recipient at 3 weeks post-
transplantation of marrow from the primary recipient studied in a. (c) 
Flow cytometric analysis showing high level of GFP expression among 
blood leukocytes (WBC), blood erythrocytes (RBC), blood platelets 
(PLT), and unfractionated marrow cells (BM), collected from a secondary 
recipient at 18 weeks post-transplantation of marrow from the primary 
recipient studied in a. BM, bone marrow.
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We next refined the phenotype of the transplantable osteopro-
genitor to the population of KLS cells, which are thought to be 
solely hematopoietic progenitors further supporting the notion 
of a dual hematopoietic-osteopoietic activity among primitive 
marrow cells. These data, together with our previous observa-
tion that osteopoietic engraftment in mice is quite robust early 
after transplantation, but decreases over time,16 led us to consider 
that the putative bipotent progenitor cell might be a short-term 
repopulating HSC. While transplantation with CD34+ KLS cells, 
the marrow population containing the short-term repopulating 
HSC, gave low levels of osteopoietic engraftment, transplanta-
tion with CD34− KLS cells resulted in almost four times as much. 
Nonetheless, the low level of engraftment by the CD34+ cells was 
significantly greater than in the negative control. Although the 
latter finding could reflect contamination of the CD34+ fraction 
with CD34− cells, the more likely interpretation is that the osteo-
poietic capacity of CD34− KLS cells decreases with maturation. 
Hence, the most primitive stem cells in the marrow compartment, 
marked by the lack of CD34 expression, would have the great-
est osteoprogenitor activity with a gradual loss of this potential as 
the cells mature, marked by increasing CD34 expression (progres-
sively brighter fluorescence as measured by flow cytometry). Once 
the cells have committed to hematopoietic differentiation within 
a specific lineage, all of their osteopoietic capacity should be lost. 
This interpretation is supported by the lack of donor-derived 
osteopoiesis from transplanted multipotent progenitor, common 
myeloid progenitor or common lymphoid progenitor cells. These 
findings implicate the population of CD34− KLS cells, which are 
highly enriched for LTR-HSC,15 as the most robust transplantable 
osteoprogenitors within the BM and suggest that these primitive 
cells lose their osteopoietic differentiation capacity as they mature 
(Figure 7).
If our working hypothesis is correct, that primitive hemato-
poietic stem/progenitor cells identified by CD34− KLS expression 
Figure 5 Engrafted cells express osteoblast markers. (a,b) Double immunohistochemical staining of bone taken from a secondary recipient 3 
weeks post-transplantation was positive for (a) both collagen I (red) and GFP (black) and (b) both osteocalcin (red) and GFP (black). Bar = 50 μm. 
The panels to the right, are digitally enlarged images of the respective boxed regions in a and b. Osteoblasts and osteocytes are indicated by thick 
and thin arrows, respectively. (c) Immunofluorescence microscopy of bone from a secondary recipient strongly stained for GFP (green) and lightly 
stained for osteocalcin (red) to minimize background fluorescence. Three yellow osteoblasts (thick arrows) and four green-yellow osteocytes (thin 
arrows) are indicated. (d) Flow cytometric analyses of culture-expanded osteoblasts before (top) and after (bottom) FACS enrichment for GFP expres-
sion. (e) Reverse transcriptase-PCR analysis showing expression of osteopontin (OPN), collagen I (Col I), and osteocalcin (OCN), but not CD45, in 
the GFP-enriched osteoblasts from d. (f) Quantitative reverse transcriptase-PCR showing the expression of five osteoblast genes compared with the 
GAPDH expression in the same cell population as in e. BM, bone marrow; Ct, threshold cycle; FACS, fluorescence-activated cell sorting; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; GFP, green fluorescent protein.
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engraft at discrete, saturable sites in the marrow space and gener-
ate local osteopoietic cells, then donor-derived osteopoiesis after 
BMT should be inhibited by cotransplantation of purified CD34− 
KLS cells, as these cells should compete with marrow CD34− KLS 
cells for engraftment. Indeed, cotransplantation of unlabeled 
CD34− KLS cells with GFP-expressing marrow cells dramatically 
reduced the contribution of unfractionated GFP+ marrow cells 
to osteopoiesis further substantiating the notion that the pool of 
CD34− KLS cells is the source of transplantable osteopoiesis and 
engrafts at defined, finite sites in the marrow microenvironment.
Although our previous report of a common retroviral 
integration site in clonogenic hematopoietic and osteopoi-
etic cells after transplantation of unfractionated, gene-marked 
marrow cells provided compelling evidence of a common 
 hematopoietic-osteopoietic primitive progenitor,2 our single cell 
secondary transplantation data are the sine qua non to establish 
dual hematopoietic-osteopoietic differentiation activity of LTR-
HSC. We showed short-term and LT hematopoietic engraftment 
and the osteopoietic engraftment in mice transplanted with the 
BM from a mouse reconstituted from a single GFP+ KLS cell. 
While it is generally accepted that all GFP-expressing blood cells 
in secondary recipients, measured by flow cytometry, were derived 
from the single GFP+ cell transplanted into primary recipients, 
the potential pitfall of these studies is inadequate evidence of 
multi-tissue differentiation. In our study, we demonstrated that 
the GFP+ cells in bone were osteoblasts/osteocytes by histologic 
localization, bright field microcopy of double immunohistochem-
ically stained bone, immunofluorescence microscopy of doubly 
stained bone, and gene expression analysis of GFP-enriched, cul-
ture-expanded cells (osteoblasts). Moreover, we excluded fusion 
as an alternative explanation by karyotype analysis. Thus, an LTR-
HSC, defined by its capacity to generate GFP+ blood and mar-
row at 16 weeks post-transplantation and to undergo self-renewal 
in primary recipients, retained sufficient potency to contribute 
robustly to both hematopoiesis and osteopoiesis in secondary 
recipients, thereby satisfying the criteria for “stemness” as defined 
by Lagasse et al.22
Notably, donor-derived osteopoiesis ranged from 5 to 8% in 
our secondary recipients; however, we would stress that the maxi-
mal contribution of donor cells to the osteopoietic compartment 
after infusion of very high doses of marrow cells is about 15% of the 
bone cells in the metaphysis and epiphysis.18 The observed engraft-
ment in bone after secondary transplantation, therefore, represents 
about a third to a half of the maximal level of engraftment. Since 
the donor origin of transplanted cells is identified by GFP expres-
sion and the transplanted marrow of the primary recipient was 
26–69% GFP+, the magnitude of engraftment we observed in the 
secondary recipients was precisely what one would predict.
If single LTR-HSC contribute significantly to the osteopoietic 
compartment after transplantation into lethally irradiated mice, 
what might account for the relatively rapid decrease in donor-
derived osteopoiesis following BMT?16 One explanation is that 
osteopoiesis in the immediate post-transplantation setting reflects 
a physiological response of donor HSC that have newly engrafted 
in endosteal niches. After restoration of the homeostatic condition 
of the niche, where HSC are maintained in a quiescent state, osteo-
poietic differentiation ceases. This interpretation argues that the 
osteopoietic activity of HSC is a genetically programmed, physio-
logically relevant response evident in the setting of hematopoietic 
cell transplantation, rather than a rare instance of developmental 
plasticity. Consistent with this view is the expression pattern of 
critical transcription factors. For example, Runx2, the master reg-
ulator of osteoblast differentiation from pluripotent mesenchymal 
progenitors,23 is highly expressed in HSCs but rapidly decreases 
with myeloid differentiation,24 analogous to the marked osteopoi-
etic differentiation potential of primitive LT-HSC that decreases 
with maturation (Figures 2c and 3a,b). Similarly, Runx1, a key 
hematopoietic transcription factor25 essential for fetal liver hema-
topoiesis,26 also contributes to fetal skeletal development.27,28 In 
addition, after clinical hematopoietic cell transplantation, circu-
lating collagen I-positive osteoprogenitors coexpress CD34 and/
or CD45 and are derived from transplanted donor hematopoietic 
cells.29 Moreover, Singh et al.6 recently reported that BMT leads 
to engraftment of functional donor-derived osteoblasts as well as 
mesenchymal progenitors consistent with our current findings 
Figure 6 Representative cytogenetic analysis of cultured osteoblasts 
obtained from secondary recipients. The X (green) and Y (red) chro-
mosomes were identified by fluorescence in situ hybridization, using 
chromosome-specific probes. Bar = 10 μm.
Figure 7 Proposed model for relative hematopoietic and osteo-
poietic contributions of primitive hematopoietic progenitors after 
transplantation. Triangles indicate decreasing differentiation potential, 
with LT-HSCs having the strongest osteopoietic activity. ST-HSCs have 
low (but detectable) activity, whereas MPPs, CMPs, and CLPs lack osteo-
poietic potential altogether. CLP, common lymphoid progenitor; CMP, 
common myeloid progenitor; LT-HSC, long-term hematopoietic stem 
cell; MPP, multipotent progenitor; ST-HSC, short-term hematopoietic 
stem cell.
LT-HSC
Lymphohematopoietic
reconstitution
potential
Osteopoietic
differentiation
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and confirming our prior observations.2,16,18 Efforts to harness 
this osteopoietic activity for the treatment of bone disorders or 
bone injury should be directed toward understanding the specific 
molecular cues that allow HSC to choose an osteoblastic fate.
MATERIALS AND METHODS
Transplantation. All animal studies were approved by the Institutional 
Animal Use and Care Committees of The Children’s Hospital of 
Philadelphia. BM was harvested from transgenic mice (FVB/N genetic 
background) expressing GFP under the control of the H2K promoter.11 
The unfractionated or FACS-sorted (FACSVantage; BD Biosciences, San 
Jose, CA) marrow cells were transplanted into 4–6 week old lethally irra-
diated (1,125 cGy) FVB/N mice by tail vein injection within 2 hours after 
irradiation, as previously described.2 For the single cell transplant studies, 
marrow cells from our GFP-expressing transgenic (FVB/N) mice were 
sorted on a FACSVantage at 1 cell/well in a 96-well plate containing 200 
μl Hank's balanced salt solution with 2% fetal bovine serum (Mediatech, 
Manassas, VA). Individual wells were screened by light and fluorescence 
microscopy to verify that they contained a single GFP-expressing cell. To 
each well, we added 1 × 105 wild-type Sca-1− cells, and then the entire 
cell graft was transplanted into lethally irradiated recipients as described 
above.
Immunohistochemical staining and analysis by microscopy. The 
immunohistochemical staining of bone sections (4-μm thickness) and 
microscopic evaluation of the metaphysis and epiphysis of femurs were 
performed as previously described.2,16 Three sections from each femur 
were studied and the mean (± SD) percentage of donor cells calculated. 
The number of animals evaluated in each experimental group is given in 
the text. Stained slides were examined on a Nikon E800 microscope (Nikon 
Instruments, Melville, NY) with either a 40x/0.95 N.A. or a 60x/0.95 N.A. 
dry objective. Photomicrographs were produced with the attached Nikon 
DXM 1200 color camera and Nikon ACT-1 Version 2.11 software (Nikon 
Instruments). Images were cropped and labeled using Photoshop CS4 and 
Illustrator CS4 (Adobe Systems, San Jose, CA).
Immunofluorescence staining and analysis by microscopy. Formalin-fixed 
specimens were decalcified, paraffin embedded and 3 μm thickness section 
were prepared for double immunofluorescence assays. The  sections were 
deparaffinized, rehydrated, and permeabilized with phosphate- buffered 
saline (PBS) 1X containing 0.12% triton X-100. Antigen retrieval was per-
formed with incubation in a chondroitinase ABC solution (0.35  IU/ml; 
Sigma-Aldrich, St Louis, MO) for 25 minutes. To block nonspecific bind-
ing of the antibodies, the sections were incubated for 45 minutes with 10% 
blocking reagent (Roche Diagnostics, Indianapolis, IN) dissolved in maleic 
buffer and fetal calf serum. Bone sections were incubated in a humidified 
chamber overnight at 4 °C with a solution of PBS 1X with 0.1% bovine serum 
albumin, 10% donkey serum (Jackson ImmunoResearch Laboratories, 
West Grove, PA), and 0.4% triton X-100. In this solution, were dissolved 
the two primary antibodies: rabbit anti-GFP (1:200, cat. no. ab290; Abcam, 
Cambridge, MA) and goat anti osteocalcin (1:100, cat. no. 7060-18-15; AbD 
Serotec, Raleigh, NC). After three washes in high salt PBS 1M, slides were 
incubated for 2 hours in the dark in the mixture of two secondary antibodies, 
with two different fluorochromes, composed by PBS 1X, 10% donkey serum, 
goat anti-rabbit (1:200, cat. no. 35552; Thermo Scientific, Waltham, MA) and 
donkey anti goat (1:200, cat. no. ab96933; Abcam) antibodies. After three 
washes in high salt PBS 1M, slides were mounted with a drop of mount-
ing medium with DAPI (4′,6-diamidino-2-phenylindole) for DNA staining 
(Sigma). Slides were stored at 4 °C in dark. Stained slides were examined on 
an inverted microscope, Zeiss Axio Observer.A1 (Carl Zeiss MicroImaging, 
Thornwood, NY) with epi-fluorescence and a 40x/0.75 NA dry objective in 
a darkened room. Photomicrographs were acquired with AxioCam MRc5 
color camera (Carl Zeiss MicroImaging) and AxioVision software. Images 
were adjusted for brightness, contrast, color balance by AxioVision LE.
Osteoblast isolation. Osteoblasts were isolated from freshly obtained bone 
and expanded in tissue culture as previously described.2
Flow cytometry. Blood or marrow cells were analyzed with a FACSAria 
flow cytometer (BD Biosciences), using commercially available antibodies 
(BD Biosciences or eBioscience, San Diego, CA). The data were analyzed 
with Cell Quest Pro Software, version 5.2.1 (BD Biosciences).
Reverse transcriptase-PCR. Total RNA was isolated from culture-
expanded osteoblast using TRIzol Reagent (Invitrogen, Carlsbad, CA). 
First-strand cDNA was synthesized from 10 μg total RNA using the 
High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, 
Foster City, CA), according to the manufacturer’s protocol. PCR was 
performed with the HotStarTaq Master Mix (Qiagen, Valencia, CA). 
Conditions for amplification were 35 cycles at 95 °C for 1 minute, 53 °C 
(collagen I and osteocalcin), 55 °C (β-actin and osteopontin), or 57 °C 
(CD45) for 1 minute, and 72 °C for 1 minute. Primer sequences were 
as follows: osteopontin, 5′-TCACCATTCGGATGAGTCTG-3′ and 
5′-ACTTGTGGCTCTGATGTTCC-3′; collagen I, 5′-AGCGGAGGTGG 
CTATGACTT-3′ and 5′-GCGCGGCTGTATGAGTTCTT-3′; osteocalcin, 
5′-CTGACCTCACAGATGCCAAG-3′ and 5′-GGAGCTGCTGTGACAT 
CC-3′; CD45, 5′-CTTCGACGGAGAGTTAATGC-3′ and 5′-GTCGCCTT 
AGCTTGACAACA-3′; β-actin, 5′-CATTGTGATGGACTCCGGAGAC 
GG-3′ and 5′-CATCTCCTGCTCGAAGTCTAGAGC-3′. Amplified prod-
ucts were then identified by 2% agarose gel electrophoresis and visualized 
with ethidium bromide and a ultraviolet transilluminator.
Quantitative reverse transcriptase-PCR. Total RNA was isolated as above. 
First-strand cDNA was synthesized from 1 μg of total RNA using a rever-
tAid H minus first-strand cDNA synthesis kit (Fermentas, Waltham, 
MA) according to the manufacturer’s instructions. Quantitative real-time 
PCR was performed using the Applied Biosystems StepOne Real-Time 
PCR System and the Fast SYBR Green Master Mix reagent. Forward and 
reverse primers were designed using http://test.idtdna.com/home/home.
aspx web site, specifying mRNA rather than genomic DNA by ensur-
ing the selected primers spanned an intron sequence. Primer sequences 
were as follows: osteopontin, 5′-GTG ATT TGC TTT TGC CTG TTT 
G-3′ and 5′-GAG ATT CTG CTT CTG AGA TGG G-3′; runx2, 5′-GTA 
GCC AGG TTC AAC GAT CTG-3′ and 5′-CCG TCC ACT GTC ACT 
TTA ATA GC-3′; osteocalcin, 5′-CTGACCTCACAGATGCCAAG-3′ and 
5′-GGAGCTGCTGTGACATCC-3′; collagen I, 5′-AAG GAT ACA GTG 
GAT TGC AGG-3′ and 5′-TCT ACC ATC TTT GCC AAC GG-3′; alkaline 
phosphatase, 5′-CTC CAA AAG CTC AAC ACC AAT G-3′ and 5′-ATT 
TGT CCA TCT CCA GCC G-3′; GAPDH, 5′-GCC TTC CGT GTT CCT 
ACC-3′ and 5′-CCT CAG TGT AGC CCA AGA TG-3′. Relative expres-
sion of the target gene was normalized to the endogenous β-actin gene 
as reference. The 2−ΔΔCt (cycle threshold) method,30 was used to calculate 
relative expression levels of the target genes.
Fluorescence in situ hybridization. Culture-expanded osteoblasts from the 
bone of secondary recipient mice were incubated for 4 hours in colcemid 
and harvested by standard methods. Directly labeled X and Y chromo-
some-specific paint probes were purchased from Applied Spectral Imaging 
(Vista, CA) and used in hybridization studies, according to the manufac-
turer’s instructions. Chromosomes were analyzed as described previously.2
Statistical analysis. Engraftment rates were compared by Student’s t-test 
(two-tailed) and one-way analysis of variance using Prism version 4 soft-
ware (GraphPad, San Diego, CA), with a P value of <0.05 considered 
 statistically significant.
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